Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.

International journal of hematology - 1 May 2004

Okikawa Yoshiko, Sakai Akira, Takimoto Yasuo, Noda Masaaki, Imagawa Jun, Katayama Yuta, Kuroda Yoshiaki, Okita Hajime, Fujimura Kingo, Kimura Akiro

Abstract excerpt

In our experience with thalidomide treatment for refractory multiple myeloma (MM), most patients with progressive disease (PD) did not show an increase in M-protein despite the tumor burden of myeloma cells. This finding led us to suspect that proliferation of immature myeloma cells showing MPC-1(-)/CD49e(-) phenotype may be a sign of PD. We report the results of consecutive analysis of the phenotype of myeloma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Division
Share to Disease Progression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Multiple Myeloma

Share to Neoplasm Proteins

Share to Plasma Cells

Share to Thalidomide

Share to Treatment Failure

Source

Identifiers

PMID: 15218967
DOI: 10.1532/ijh97.04005

Genes

CD38

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.PMID 15218967Read ↗

Phenotypic difference of normal plasma cells from mature myeloma cells.Semantic proximity Read ↗

A new phenotypic classification of bone marrow plasmacytosis.Semantic proximity Read ↗

The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.Semantic proximity Read ↗

The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state.Semantic proximity Read ↗

The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma.Semantic proximity Read ↗

Plasma cell dedifferentiation in refractory multiple myeloma.Semantic proximity Read ↗

Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.Semantic proximity Read ↗

The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.Semantic proximity Read ↗

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Semantic proximity Read ↗

Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma.Semantic proximity Read ↗

Identification of a myeloma variant with aggressive biological and clinical characteristics: "early" plasma cell meningitis.Semantic proximity Read ↗

Myelomatous ascites: Flow cytometric diagnosis and evolution of phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.